Loading...
OTCM
PYCXF
Market cap552mUSD
Apr 15, Last price  
0.67USD
Name

PYC Therapeutics Ltd

Chart & Performance

D1W1MN
P/E
P/S
26.82
EPS
Div Yield, %
Shrs. gr., 5y
7.05%
Rev. gr., 5y
-40.58%
Revenues
22m
+39.56%
52,5560275,38590,7521,274,942596,2562,358,5321,918,368711,891739,391829,1191,0762,762,73348,46002,395,7063,074,36816,042,82115,806,25622,059,314
Net income
-38m
L+65.54%
-1,587,323-3,991,475-3,888,673-4,483,938-4,490,920-4,572,825-3,605,169-3,904,524-3,439,624-3,257,695-2,991,479-3,978,672-1,950,837-7,433,997-4,079,767-6,822,215-17,767,586-13,863,159-22,788,985-37,725,411
CFO
-39m
L+58.01%
00000000-2,315,203-3,200,291-2,481,246-3,166,729-1,883,136-6,707,273-5,125,413-5,748,405-11,791,314-21,782,280-24,421,686-38,588,501
Earnings
Aug 27, 2025

Profile

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders, including Motor Neurone Disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
IPO date
Mar 30, 2005
Employees
23
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
22,059
39.56%
15,806
-1.47%
Cost of revenue
60,917
39,163
Unusual Expense (Income)
NOPBT
(38,857)
(23,357)
NOPBT Margin
Operating Taxes
(17,559)
(15,806)
Tax Rate
NOPAT
(21,298)
(7,551)
Net income
(37,725)
65.54%
(22,789)
64.39%
Dividends
Dividend yield
Proceeds from repurchase of equity
90,489
10,698
BB yield
-19.16%
-5.88%
Debt
Debt current
310
178
Long-term debt
1,916
275
Deferred revenue
Other long-term liabilities
274
180
Net debt
(64,649)
(15,118)
Cash flow
Cash from operating activities
(38,589)
(24,422)
CAPEX
(307)
(491)
Cash from investing activities
(307)
(477)
Cash from financing activities
90,194
11,441
FCF
(23,698)
(9,027)
Balance
Cash
66,875
15,572
Long term investments
Excess cash
65,772
14,781
Stockholders' equity
81,055
28,443
Invested Capital
16,670
14,157
ROIC
ROCE
EV
Common stock shares outstanding
3,935,911
3,248,815
Price
0.12
114.29%
0.06
-13.85%
Market cap
472,309
159.61%
181,934
-13.04%
EV
408,219
167,508
EBITDA
(37,789)
(22,475)
EV/EBITDA
Interest
49
27
Interest/NOPBT